TY - JOUR
T1 - The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females
AU - Patel, Dimpi
AU - Mohanty, Prasant
AU - Di Biase, Luigi
AU - Wang, Yan
AU - Shaheen, Mazen H.
AU - Sanchez, Javier E.
AU - Horton, Rodney P.
AU - Gallinghouse, G. Joseph
AU - Zagrodzky, Jason D.
AU - Bailey, Shane M.
AU - Burkhardt, J. David
AU - Lewis, William R.
AU - Diaz, Alberto
AU - Beheiry, Salwa
AU - Hongo, Richard
AU - Al-Ahmad, Amin
AU - Wang, Paul
AU - Schweikert, Robert
AU - Natale, Andrea
PY - 2010/3
Y1 - 2010/3
N2 - Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.
AB - Aims To assess whether treatment with statins or renin-angiotensin- aldosterone system (RAAS) inhibitors as potential procedural 'augmenting agents' improved atrial fibrillation (AF) catheter ablation recurrence rates in post-menopausal females (PMFS). Methods and results Five hundred and eighteen consecutive female patients had undergone AF catheter ablation from January 2005 to May 2008. Post-menopausal females were selected and procedure outcomes were compared between cohorts of PMFS treated with statins or RAAS inhibitors to untreated PMFS. Out of 408 PMFS, 36 (8.8) were treated with a combination of RAAS inhibitors and statins, thus were excluded leaving a total of 372 (91.2) patients in the study. Out of 372 patients, 111 (29.8) were on statins (Group 1), 59 (15.9) on RAAS inhibitors (Group 2), and 202 (54.3) without RAAS inhibitors or statins [(Group 3) control population]. Over a mean follow-up time of 24 ± 8.3 (median 25) months, 78 (70.6) in Group 1, 38 (65.4) in Group 2, and 139 (68.8) in Group 3 had procedural success. Statin or RAAS inhibitor use did not predict lower recurrence rates [hazard ratio (HR): 1.26, P = 0.282 and HR: 1.14, P = 0.728, respectively]. When compared with controls, no difference in the cumulative incidence of recurrence was found with statin or RAAS inhibitors use (P = 0.385 and P = 0.761, respectively). Conclusion Treatment with statins or RAAS inhibitors did not improve catheter ablation success rates among PMFS. Thereby, from a clinical standpoint, PMFS should not be started on these treatments as a procedural 'augmenting agent' at this time.
KW - Atrial fibrillation
KW - Post-menopausal female
KW - Pulmonary vein antrum isolation
KW - Renin-angiotensin-aldosterone system blockers
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=77749324818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77749324818&partnerID=8YFLogxK
U2 - 10.1093/europace/eup387
DO - 10.1093/europace/eup387
M3 - Article
C2 - 20064822
AN - SCOPUS:77749324818
SN - 1099-5129
VL - 12
SP - 322
EP - 330
JO - Europace
JF - Europace
IS - 3
ER -